March 9, 2016
(Science) – Adversaries in the legal battle over the rights to the CRISPR gene-editing technology are preparing to fire their initial shots. In two documents filed with the U.S. Patent Trial and Appeal Board last week, lawyers for the Regents of the University of California (UC) and the Broad Institute (BI) in Cambridge, Massachusetts, offered hints at how they will lay claim to the breakthrough technology and its financial spoils. And UC lawyers have made accusations of error and deception that, if true, could invalidate BI’s patents early in the proceedings.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.